NEW YORK (GenomeWeb News) – Lucigen and Research Corporation Technologies on Wednesday announced a commercialization and distribution partnership for the first Escherichia coli-based recombinant system without endotoxin.
The CleanColi Expression System is for protein expression and contains a genetically modified lipopolysaccharide that does not create an endotoxic response in human cells. Because of this, researchers will be able to increase their productivity since they will no longer need to remove unwanted endoxin, Lucigen and RCT said.
Lucigen will produce and sell kits containing CleanColi competent cells and provide contract research services for the CleanColi Expression System. The company also launched the CleanColi competent cell line.
RCT will manage the CleanColi commercial licensing programs.
Financial and other terms of the deal were not disclosed.